http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S5795990-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8b9036c33bbe3f4ea428655b76200f7c |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-14 |
| filingDate | 1980-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc52fc3992c8731b7e2e693b9132b65a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6dc73928470161c6bff812233625b2da http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e864ac544418eb30df4b29ed509969d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f0ecfb618b277d2a2440e8f5321744b |
| publicationDate | 1982-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-S5795990-A |
| titleOfInvention | 1a-n-methoxycarbonylmitomycin a and antitumor agent comprising it |
| abstract | NEW MATERIAL:1a-N-Methoxycarbonylmitomycin shown by the formula. n USE: An antitumor agent. Having lower systemic side effects and myleotoxicity than 1a-N-ethoxycarbonylmitomycin A. An intravenous, intra-abdominal, or peroral administration is possible and its dose is 1W5mg/kg/day. n PROCESS: Mitomycin A is reacted with methyl chloroformate in the presence of a base (e.g., sodium hydrogencarbonate) in an inert solvent (e.g., THF) to give a compound shown by the formula. In the reaction, methyl chloroformate in a molar amount 1W5 times that of mitomycin A is used and the base in a molar amount 1W30 times that of mitomycin A, and the reaction is carried out at 0W30°C. n COPYRIGHT: (C)1982,JPO&Japio |
| priorityDate | 1980-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 26.